Form 4: Immunovant Executive Sells Shares to Cover Tax Obligations

Julia G. Butchko, Chief Development Officer of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On July 17, 2024, Julia G. Butchko, Chief Development Officer of Immunovant, Inc., sold 2,698 shares of common stock at a weighted average price of $29.64 and 169 shares at a weighted average price of $30.55.
• These sales were to cover tax withholding obligations related to the vesting of 6,261 restricted stock units (RSUs) on July 12, 2024, which were part of a grant of 100,188 RSUs on April 12, 2023.
• The sales were mandated by Immunovant's policy requiring tax withholding obligations to be funded by a 'sell to cover' transaction and do not represent a discretionary transaction by Butchko.
• Following the reported transactions, Butchko beneficially owns 443,986 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (sale of shares for tax obligations) and doesn't indicate any significant positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Executives often sell shares to cover tax obligations related to equity compensation.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates